Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05465031
Other study ID # LCZ696ABM001.001
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date February 2023
Est. completion date February 2028

Study information

Verified date July 2022
Source Silesian Centre for Heart Diseases
Contact Mateusz Tajstra, MD, PhD, Associate Professor
Phone +48323733860
Email mateusztajstra@wp.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retrospective, small, single-center studies have shown that treatment with sacubitril/valsartan may reduce the risk of cancer-therapy induced cardiotoxicity, or reverse contractile dysfunction caused by anti-cancer therapy. However, no large randomized data confirmed these findings. Therefore, the Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent) study, has been designed to verify, whether the preventive use of sacubitril/valsartan administered in the doses recommended in patients with HFrEF in breast cancer patients undergoing adjuvant chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will reduce the incidence of cardiotoxicity defined as impaired left ventricular systolic function on cardiac magnetic resonance imaging (MRI). In the trial, a total of 480 patients with histologically confirmed breast cancer, who are eligible for chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will undergo 1:1 randomization to either preventive treatment with sacubitril/valsartan or placebo. The patients will be followed for 24 months, and will have repetitive efficacy and safety examinations, including echocardiography, MRI, electrocardiography including 24-h Holter monitoring, blood tests, functional capacity tests and quality of life assessment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 600
Est. completion date February 2028
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent - Female gender, aged 18 years and over - Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (ER, PR, HER2, Ki67) - Ability to take oral medication and willingness to adhere to the planned regimen - Tumor grade IA-IIIC or oligometastatic grade IV - Radical treatment plan including surgery - Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and/or anti-HER2 drugs - ECOG 0-2 general status - LVEF = 50% as assessed by echocardiography - Sinus rhythm Exclusion Criteria: - Prior anthracycline-based chemotherapy and/or left-sided radiotherapy (prior to diagnosis of the cancer being the present cause of therapy) - Clinically relevant HF (NYHA II-IV) - MI within the last < 3 months - Symptomatic hypotension or SBP < 90 mmHg - Significant valvular disease, symptomatic coronary artery disease (CCS>2), significant AV block, symptomatic sinus node dysfunction - Expected survival <12 months - GFR<30 ml/min/1.73 m2 (screening visit) - K+>5.5mmol/L (screening visit) - Contraindications to ACE-I/ARB or LCZ696 if not listed among criteria - Active untreated liver disease - Pregnancy - Contraindications to cardiac MRI, including allergy to gadolinium-containing contrast agent or presence of implanted materials or devices prohibited for MRI - Conditions/circumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug/alcohol dependence, poorly controlled mental illness)

Study Design


Intervention

Drug:
Sacubitril-valsartan
Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.

Locations

Country Name City State
Poland Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch Gliwice Silesia
Poland Holy Cross Cancer Centre, Cardio-Oncology Division Kielce Swietokrzyskie
Poland Regional Cancer Centre in Opole Opole Opolskie
Poland Silesian Center for Heart Diseases Zabrze Silesia

Sponsors (2)

Lead Sponsor Collaborator
Silesian Centre for Heart Diseases Medical Research Agency

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in left ventricular ejection fraction = 5% Reduction of LVEF assessed on magnetic resonance imaging (MRI) At 12 months from the randomization visit
Secondary Death from any cause or hospitalization for heart failure Composite clinical endpoint From Randomization till the end of blinded therapy - at 24 months
Secondary Death from any cause From Randomization till the end of blinded therapy - at 24 months
Secondary Death from cardiovascular causes From Randomization till the end of blinded therapy - at 24 months
Secondary Hospitalization for other cardiovascular causes From Randomization till the end of blinded therapy - at 24 months
Secondary Decrease in left ventricular ejection fraction = 5% Reduction of LVEF assessed on echocardiography From Randomization till the end of blinded therapy - at 24 months
Secondary Occurrence of diastolic dysfunction (UKG) within 24 months of randomization Diastolic dysfunction assessed on echocardiography From Randomization till the end of blinded therapy - at 24 months
Secondary - Development of pathological pericardial fluid volume or increase in pericardial fluid volume from baseline Assessed with any available clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Occurrence of cardiac tamponade Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Occurrence of pericarditis Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Occurrence of myocarditis Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Development of ventricular arrhythmias Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Development of supraventricular arrhythmias Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Presence of conduction disturbances Assessed with any clinical modality From Randomization till the end of blinded therapy - at 24 months
Secondary Changes in corrected QT interval From Randomization till the end of blinded therapy - at 24 months
Secondary Changes in BNP, NT pro-BNP, troponin T or troponin I levels Assessed with serial laboratory measurements From Randomization till the end of blinded therapy - at 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A